New research suggests GLP-1 receptor agonists like semaglutide significantly reduce respiratory exacerbations. A UK electronic health records study presented at the European Respiratory Society Congress found semaglutide associated with a 38% to 40% reduction in asthma attacks and a 20% to 21% reduction in COPD flare-ups, independent of weight loss. Separately, a University of Pittsburgh review suggests GLP-1s could alleviate obstructive sleep apnea by reducing obesity-related airway collapse and leptin resistance.
GLP-1 respiratory exacerbation reduction
- ▪A UK electronic health records study presented at the European Respiratory Society Congress in Barcelona, Spain, linked GLP-1 receptor agonists to reduced asthma and COPD exacerbations
- ▪The reduction in respiratory exacerbations varied by drug, with exenatide showing a 23% reduction and dulaglutide showing a 12% reduction
- ▪Patients with asthma or COPD starting any GLP-1 receptor agonist had a 14% lower risk of exacerbations compared to new users of sulfonylureas
- ▪The UK electronic health records study found no change in respiratory exacerbations for patients starting liraglutide or lixisenatide
Semaglutide asthma attack prevention
- ▪Semaglutide use was associated with an approximate 38% to 40% reduction in asthma attacks, particularly in patients with more pronounced asthma
- ▪In the UK electronic health records study, semaglutide was associated with a 30% overall reduction in asthma and COPD exacerbations
- ▪Semaglutide use was associated with a 20% to 21% reduction in chronic obstructive pulmonary disease flare-ups
Obesity sleep apnea mechanisms
- ▪Excess body weight around the neck narrows the airway lumen, making the pharynx more likely to collapse during sleep
- ▪The Wisconsin Sleep Cohort Study found that a 10% gain in body weight was associated with a 32% increase in the apnea-hypopnea index
- ▪Obesity is present in 60% to 70% of patients with obstructive sleep apnea and represents the primary modifiable risk factor
- ▪Body fat around the chest and abdomen reduces lung expansion, decreasing the tension that helps keep the pharynx open
- ▪Obesity-induced leptin resistance blunts the respiratory drive, as leptin normally acts as a respiratory stimulant
- ▪A literature review by University of Pittsburgh researchers published on September 3, 2026, suggests GLP-1 receptor agonists could benefit patients with obstructive sleep apnea
Metabolic factors pulmonary effects
- ▪The UK electronic health records study found that semaglutide's respiratory benefits were not modified by baseline body mass index, HbA1c, or weight change
- ▪The UK electronic health records study found that asthma and COPD exacerbation reductions did not appear to be modified by age, smoking, or eosinophil count
Clinical trial prescribing needs
- ▪Researchers and medical experts emphasized that the observational findings on GLP-1 drugs and respiratory exacerbations must be confirmed in randomized clinical trials
- ▪Professor Chloe Bloom stated that patients should not start GLP-1 receptor agonists specifically for lung conditions outside current prescribing guidance
- ▪Dr. Richard Schwab stated that GLP-1 treatments for sleep apnea must be used in conjunction with Continuous Positive Airway Pressure therapy
Story comments
Loading comments…